primary sclerosing cholangitis
Information
- Disease name
- primary sclerosing cholangitis
- Disease ID
- DOID:0060643
- Description
- "A sclerosing cholangitis characterized by fibroobliterative inflammation of the biliary tract, leading to cirrhosis and portal hypertension." [url:https\://www.ncbi.nlm.nih.gov/pubmed/7877651]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04595825 | Active, not recruiting | Phase 2 | CM-101 in PSC Patients -The SPRING Study | October 1, 2020 | September 2025 |
| NCT04981756 | Active, not recruiting | PSC Clinical Epidemiology in China | April 7, 2021 | December 2023 | |
| NCT00179439 | Completed | NPDT Evaluation in Children With CFTR and (PSC) | January 2004 | January 2006 | |
| NCT00325013 | Completed | Phase 1 | Evaluation of DHA for the Treatment of PSC | December 2005 | May 2012 |
| NCT00630942 | Completed | Phase 1 | Minocycline in Primary Sclerosing Cholangitis (PSC) | February 2003 | May 2007 |
| NCT00951327 | Completed | Cholangioscopy Using Narrow Band Imaging (NBI) in Patients With Primary Sclerosing Cholangitis (PSC) Undergoing Endoscopic Retrograde Cholangiopancreatogram (ERCP) | November 2008 | August 2010 | |
| NCT05866809 | Completed | Phase 2 | Evaluation of the Safety and Efficacy of HK-660S in Patients With Primary Sclerosing Cholangitis | October 28, 2021 | July 24, 2023 |
| NCT00955149 | Completed | Phase 1 | Erlotinib for Chemoprevention in Trisomy 7 Positive Primary Sclerosing Cholangitis (PSC) | August 2009 | April 2013 |
| NCT01085760 | Completed | Phase 1 | A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis | February 2010 | November 2011 |
| NCT01088607 | Completed | Phase 1 | Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis | October 2010 | June 2017 |
| NCT02978339 | Completed | Phase 1/Phase 2 | A Study Evaluating the Safety and Efficacy of Curcumin in Patients With Primary Sclerosing Cholangitis (PSC) | June 9, 2017 | January 8, 2019 |
| NCT03041662 | Completed | Surveillance Study for Early Detection of Cholangiocarcinoma (CCA) in Primary Sclerosing Cholangitis (PSC) | October 31, 2011 | November 30, 2020 | |
| NCT02736708 | Completed | Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy for PSC Biliary Strictures | January 2013 | May 2020 | |
| NCT02884557 | Completed | N/A | NKT Role in the Regulation of the Inflammatory Bowel Disease | May 2013 | August 28, 2019 |
| NCT02943460 | Completed | Phase 2 | Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis | November 29, 2016 | May 18, 2020 |
| NCT03069976 | Completed | N/A | "Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children" | January 2016 | August 2021 |
| NCT01322386 | Completed | Phase 1 | Gastrointestinal Microbiota in Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | May 2007 | January 2012 |
| NCT01556412 | Completed | Endoscopic Ultrasound as an Early Diagnostic Tool for Primary Sclerosing Cholangitis | March 2009 | November 2012 | |
| NCT04480840 | Completed | Phase 2 | Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) | July 27, 2020 | March 18, 2024 |
| NCT01755507 | Completed | Phase 2 | Norursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis | December 2012 | December 2015 |
| NCT01798953 | Completed | Surgical Reconstruction in Ulcerative Colitis With Primary Sclerosing Cholangitis | January 2010 | November 2013 | |
| NCT01802073 | Completed | Phase 3 | Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects | January 2012 | August 2015 |
| NCT01879735 | Completed | Phase 1 | Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT | June 2013 | September 2014 |
| NCT01880606 | Completed | Endomicroscopy in Primary Sclerosing Cholangitis Related Inflammatory Bowel Disease Surveillance | August 2011 | June 2014 | |
| NCT02239211 | Completed | Phase 2 | A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis | September 8, 2015 | October 23, 2018 |
| NCT04024813 | Completed | Phase 2 | A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC | November 12, 2019 | January 9, 2020 |
| NCT02247934 | Completed | Development of a Patient-Reported Outcome Measure to Assess Symptoms in Patients With Primary Sclerosing Cholangitis (PSC) | October 2014 | October 2015 | |
| NCT03809559 | Completed | Repeatability and Reproducibility of Quantitative MRCP | July 19, 2018 | March 8, 2019 | |
| NCT02464020 | Completed | Phase 1 | A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis | July 2015 | December 1, 2018 |
| NCT03722576 | Completed | Phase 2 | Vidofludimus Calcium for Primary Sclerosing Cholangitis | June 17, 2019 | June 30, 2020 |
| NCT02653625 | Completed | Phase 2 | PERSEUS: Preliminary Efficacy and Safety of Cenicriviroc in Adult Participants With Primary Sclerosing Cholangitis | March 14, 2016 | August 31, 2017 |
| NCT03099603 | Completed | Phase 1 | A Study of HTD1801 in Healthy Subjects | March 24, 2017 | October 3, 2017 |
| NCT02704364 | Completed | Phase 2 | Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis | March 2016 | June 2017 |
| NCT02712736 | Completed | N/A | Quality of Life in Patients With Primary Sclerosing Cholangitis | July 1, 2016 | September 22, 2018 |
| NCT05462093 | Not yet recruiting | N/A | Clinical Application of Annual Liver Multiscan and MRCP+ in Primary Sclerosing Cholangitis | July 2022 | July 2029 |
| NCT06455280 | Not yet recruiting | Phase 1 | SIPLIZUMAB in AILD and LT | June 1, 2024 | March 31, 2026 |
| NCT06061341 | Not yet recruiting | TruGraf Liver Gene Expression Serial Test | April 2024 | December 2026 | |
| NCT06095986 | Not yet recruiting | Phase 2 | A Study Evaluating the Safety, Tolerability, and Efficacy of Aramchol Meglumine in Primary Sclerosing Cholangitis | June 2024 | December 2026 |
| NCT05835505 | Recruiting | Phase 2 | Detoxification of the Liver In PSC (Dolphin) | December 12, 2023 | December 1, 2025 |
| NCT02137668 | Recruiting | Phase 1 | Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin | July 2010 | July 2028 |
| NCT03175471 | Recruiting | MRI Based Biomarkers in Pediatric Autoimmune Liver Disease | January 17, 2017 | January 30, 2027 | |
| NCT03178630 | Recruiting | MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease | February 20, 2017 | February 2031 | |
| NCT03183570 | Recruiting | Early Phase 1 | Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT | November 8, 2017 | April 14, 2025 |
| NCT03445585 | Recruiting | Biobank for Cholestatic Liver Diseases. | January 2017 | January 2050 | |
| NCT03561584 | Recruiting | Phase 2 | Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis | July 1, 2018 | November 1, 2024 |
| NCT03710122 | Recruiting | Phase 2/Phase 3 | Vancomycin for Primary Sclerosing Cholangitis | January 23, 2020 | November 30, 2026 |
| NCT04133792 | Recruiting | Phase 3 | Effect of Simvastatin on the Prognosis of Primary Primary Sclerosing Cholangitis (PSC) | October 1, 2020 | May 15, 2027 |
| NCT04181138 | Recruiting | Primary Sclerosing Cholangitis in Children | December 30, 2021 | May 2029 | |
| NCT04309773 | Recruiting | Phase 3 | Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy | April 6, 2021 | March 2025 |
| NCT04663308 | Recruiting | Phase 2 | A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) | December 18, 2020 | December 2025 |
| NCT04685200 | Recruiting | Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach | March 31, 2023 | October 31, 2024 | |
| NCT04753996 | Recruiting | Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients | March 8, 2021 | January 2025 | |
| NCT05181332 | Recruiting | Predictive Models of Hepatic Decompensation and Survival Outcomes in Pediatric Patients With Cirrhosis | January 1, 2021 | December 31, 2024 | |
| NCT05295680 | Recruiting | Phase 2 | Oral Hymecromone to Treat Adolescents and Adults With Primary Sclerosing Cholangitis. | May 10, 2023 | May 2025 |
| NCT05463445 | Recruiting | Multicenter Observational Study of PSC and IgG4-SC in China | July 1, 2022 | July 31, 2023 | |
| NCT05618145 | Recruiting | National Database on Primary Sclerosing Cholangitis (PSC) | October 21, 2022 | October 21, 2032 | |
| NCT05627362 | Recruiting | Phase 2 | A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis. | January 27, 2023 | December 16, 2024 |
| NCT05642468 | Recruiting | Phase 2 | Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis | January 9, 2023 | June 14, 2025 |
| NCT05750498 | Recruiting | A-LiNK: Improving Outcomes in Autoimmune Liver Disease | April 28, 2022 | June 30, 2033 | |
| NCT05876182 | Recruiting | Phase 2 | Vancomycin in Primary Sclerosing Cholangitis in Italy | June 15, 2023 | June 2026 |
| NCT05896137 | Recruiting | Phase 2 | CS0159 in Chinese Patients With PSC (Primary Sclerosing Cholangitis) | August 7, 2023 | December 2024 |
| NCT05912387 | Recruiting | Early Phase 1 | Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study | May 31, 2023 | December 31, 2025 |
| NCT06026449 | Recruiting | N/A | Gluten-free Diet in PSC and IBD | January 1, 2023 | August 30, 2026 |
| NCT06197308 | Recruiting | Early Phase 1 | Evaluation of an Oral Microbiota-based Therapeutic as a Treatment Option for PSC | March 1, 2024 | September 1, 2025 |
| NCT06286709 | Recruiting | Phase 2 | FAecal Microbiota Transplantation in primaRy sclerosinG chOlangitis | March 27, 2024 | July 29, 2026 |
| NCT06351696 | Recruiting | N/A | The Effects of Bromelain Supplement in Patients With Ulcerative Colitis | April 20, 2024 | August 10, 2024 |
| NCT03890120 | Terminated | Phase 3 | Study of Cilofexor in Adults With Primary Sclerosing Cholangitis | March 27, 2019 | December 23, 2022 |
| NCT01142323 | Terminated | Phase 1/Phase 2 | Pilot Study of Fenofibrate for PSC | October 2010 | December 2012 |
| NCT03394781 | Terminated | Phase 2 | A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) | January 22, 2018 | January 31, 2019 |
| NCT00059202 | Terminated | Phase 2/Phase 3 | Trial of High-dose Urso in Primary Sclerosing Cholangitis | July 2002 | June 2008 |
| NCT04060147 | Terminated | Phase 1 | Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis | October 17, 2019 | September 2, 2021 |
| NCT00953615 | Terminated | Phase 2 | Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) | April 2006 | May 2009 |
| NCT03516006 | Unknown status | Phase 1/Phase 2 | Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis | January 2017 | January 2024 |
| NCT01398917 | Unknown status | Phase 3 | Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis | May 2011 | May 2015 |
| NCT01688024 | Unknown status | Phase 2 | Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis | September 2012 | September 2019 |
| NCT01549795 | Unknown status | N/A | Liver Transplantation for Hilar Cholangiocarcinoma in Association With Neoadjuvant Radio- and Chemo-therapy | January 2012 | |
| NCT02701166 | Unknown status | Phase 3 | The Effect of Bezafibrate on Cholestatic Itch | February 2016 | April 2018 |
| NCT04678219 | Unknown status | N/A | A Pilot Study Examining Diet in Primary Sclerosing Cholangitis | August 28, 2020 | December 2021 |
| NCT03337074 | Unknown status | Paternally Inherited Phenotypes in Cholestasis | February 8, 2017 | April 30, 2020 | |
| NCT00161148 | Unknown status | Phase 3 | Probiotics in Patients With Primary Sclerosing Cholangitis | January 2005 | May 2006 |
| NCT02446665 | Unknown status | N/A | Disease Status in Primary Sclerosing Cholangitis by Elastography | October 2014 | December 2022 |
| NCT03872921 | Unknown status | Phase 3 | norUrsodeoxycholic Acid vs Placebo in PSC | February 8, 2018 | December 2023 |
| NCT03951324 | Unknown status | Volumetric Laser Endomicroscopy's (VLE) Diagnostic Accuracy Validation Study: Impact on Clinical Management Study | May 10, 2019 | December 31, 2019 | |
| NCT02247622 | Unknown status | Telomere Length and Other Parameters of Telomere Dysfunction in PSC and Colitis | February 2012 | September 2014 | |
| NCT00476814 | Unknown status | NPD Measurements in PSC Patients | |||
| NCT05376228 | Unknown status | A Systems Biology Approach for Identification of Host and Microbial Mechanisms and Druggable Targets for the Treatment of PSC-IBD | February 1, 2022 | April 1, 2023 | |
| NCT02605213 | Unknown status | Phase 4 | Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients | September 2015 | February 2016 |
| NCT03743272 | Unknown status | Repeatability and Reproducibility of Multiparametric MRI | June 3, 2017 | November 1, 2022 | |
| NCT03678480 | Withdrawn | Phase 2 | A Study of HTD1801 in Adolescents With Primary Sclerosing Cholangitis (PSC) | March 1, 2021 | November 4, 2021 |
| NCT00588458 | Withdrawn | Phase 2 | The Value of CT Cholangiography in Primary Sclerosing Cholangitis | March 2007 | February 2009 |
| NCT03216876 | Withdrawn | Phase 1 | A Study Of Ursolic Acid For Primary Sclerosing Cholangitis | September 2017 | July 2019 |
| NCT03035058 | Withdrawn | Phase 3 | Efficacy and Safety of Vedolizumab Intravenous (IV) in the Treatment of Primary Sclerosing Cholangitis in Subjects With Underlying Inflammatory Bowel Disease | February 2017 | January 2021 |
| NCT04015310 | Withdrawn | Quantitative Magnetic Resonance Imaging in Biliary Disease: Health Economics Study | December 21, 2020 | March 31, 2021 | |
| NCT03046901 | Withdrawn | N/A | Vancomycin Treatment in Recurrent PSC in Liver Transplant Patients | December 7, 2016 | February 25, 2019 |
- Disase is a (Disease Ontology)
- DOID:14268
- Cross Reference ID (Disease Ontology)
- GARD:1280
- Cross Reference ID (Disease Ontology)
- ICD10CM:K83.01
- Cross Reference ID (Disease Ontology)
- MESH:D015209
- Cross Reference ID (Disease Ontology)
- MIM:613806
- Cross Reference ID (Disease Ontology)
- NCI:C4828
- Cross Reference ID (Disease Ontology)
- ORDO:171
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:4032000
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0566602
- OrphaNumber from OrphaNet (Orphanet)
- 171
- MedGen concept unique identifier (MedGen Concept name)
- C0566602
- MedGen unique identifier (MedGen Concept name)
- 107565